Kaposi Sarcoma Market

Market Insights

Kaposi sarcoma is caused by the infection of a virus called Kaposi sarcoma-associated herpes virus (KSHV). The disease prevalence is varied around the globe; there are four types of Kaposi sarcoma, such as AIDS-KS, immunocompromised, classic or sporadic, and endemic. Technological advancements in drug delivery, such as targeted immunotherapy and nanomedicines, are utilized to facilitate the cytotoxic payload through the blood vessels in Kaposi sarcoma tumors, which usually develop from the cells that line the lymph or blood vessels.

For the purpose of this study, the global Kaposi sarcoma market is studied in terms of treatment types and geography. The drug classes studied in the report include chemotherapy, which is further categorized as “alkaloids and liposomal anthracyclines studied in the report include chemotherapy, which is further categorized as “alkaloids and liposomal anthracyclines,” immunotherapy, HAART, radiation therapy, and surgical procedures. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.The geographic segmentation of the global Kaposi sarcoma market is performed for the regions of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global Kaposi sarcoma market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global Kaposi sarcoma market. The key players profiled in this report are Aphios Corp., Cytori Therapeutics, Inc., Bristol-Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F.Hoffman La-Roche, Inc., Johnson & Johnson, Merck & Co., Inc., and Pfizer, Inc.

Based on treatment types, the global Kaposi sarcoma market is categorized into:

• Chemotherapy
• Alkaloids
• Liposomal Anthracyclines
• Immunotherapy
• Highly Active Antiretroviral Therapy (HAART)
• Radiation Therapy
• Surgical Procedures

The rising prevalence of AIDs-related Kaposi sarcoma, the increasing number of iatrogenically immunocompromised patients, and the urgent need for novel drug discovery in treating subtypes such as classic Kaposi sarcoma found in the Eastern Mediterranean region are driving the Kaposi sarcoma market. Furthermore, an increase in the number of diagnostic centers, as well as increased physician awareness of disease etiology, will propel Kaposi sarcoma’s market penetration. In 2016, the highly active antiretroviral therapy (HAART) segment held the largest market share due to factors such as the rising prevalence of AIDS, as patients suffering from HIV infection are prone to developing Kaposi sarcoma, and the proactive government initiative such as the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to fight AIDS-KS.

Chemotherapy will be the fastest-growing segment throughout the forecast period of 2017–2025, primarily due to factors such as technological advancement in the drug formulation, e.g., paclitaxel nanosomal formulation utilized as a topical treatment for AIDS-KS, surpassing the drug biotransformation, which is toxic to liver cells. Promising pipeline with excellent bioequivalence studies such as AT-0918 (Cytori Therapeutics, Inc.). Aldoxorubicin (CytRx Corporation) utilizes an acid-sensitive linker that selectively binds to albumin to allow the cytotoxic payload to accumulate near the tumor and spare the surrounding healthy tissues. The major players in the Kaposi sarcoma market are Aphios Corp., Cytori Therapeutics, Inc., Bristol-Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F. Hoffman-La Roche, Inc., Johnson & Johnson, Merck & Co., Inc., and Pfizer, Inc.

For the purpose of this study, the global Kaposi sarcoma market is categorized into the following regional and country-specific markets:

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• rest of Latin America

Middle East and Africa

• GCC
• Rest of the Middle East and Africa

In 2016, North America was found to be the largest market for Kaposi sarcoma. According to the American Cancer Society, in 2016, the occurrence rate of Kaposi sarcoma was 6 cases per million people. More prevalent in Afro-American men. The dominance of North America is mainly attributed to the presence of key drivers such as the rising prevalence of AIDS-KS, an affordable reimbursement scenario, and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the presence of major pharmaceutical players involved in Kaposi’s sarcoma research and rising public health awareness resulting in early disease diagnosis and treatment.

Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. Factors that are anticipated to propel market growth are the increasing number of AIDS patients with Kaposi sarcoma complications, increasing disposable incomes, and a supportive regulatory environment for Kaposi sarcoma drug products. Moreover, factors such as developing health infrastructure and proactive government initiatives to fight AIDS-KS in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of the Kaposi sarcoma market in Latin America, the Middle East, and Africa in the near future.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Kaposi Sarcoma Market Portraiture
2.1.1. Global Kaposi Sarcoma Market, by Treatment Type, 2016
2.1.2. Global Kaposi Sarcoma Market, by Geography, 2016

Chapter 3. Kaposi Sarcoma: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Kaposi Sarcoma Market, by Treatment Type
4.3. Chemotherapy
4.3.1. Alkaloids
4.3.2. Liposomal Anthracyclines
4.4. Immunotherapy
4.5. Highly Active Antiretroviral Therapy (HAART)
4.6. Radiation Therapy
4.7. Surgical Procedures

Chapter 5. Global Kaposi Sarcoma Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Kaposi Sarcoma Market Analysis, 2015 – 2025
5.2.1. North America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.2.2. North America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Kaposi Sarcoma Market Analysis, 2015 – 2025
5.3.1. Europe Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.3.2. Europe Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. France
5.3.2.4. Rest of Europe
5.4. Asia Pacific Kaposi Sarcoma Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. India
5.4.2.4. Rest of APAC
5.5. Latin America Kaposi Sarcoma Market Analysis, 2015 – 2025
5.5.1. Latin America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Kaposi Sarcoma Market Analysis, 2015 – 2025
5.6.1. MEA Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.6.2. MEA Kaposi Sarcoma Market, by Region, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Aphios Corp.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Bristol Myers Squibb Company
6.3. Cytori Therapeutics, Inc.
6.4. CytRx Corporation
6.5. Eli Lilly and Co.
6.6. GlaxoSmithKline plc.
6.7. F.Hoffman La-Roche, Inc.
6.8. Johnson and Johnson
6.9. Merck & Co., Inc.
6.10. Pfizer, Inc.
6.11. Other Notable Players

List of Figures

FIG. 1 Kaposi Sarcoma: Market Segmentation
FIG. 2 Global Kaposi Sarcoma Market Share, by Treatment Type, 2016 (Value %)
FIG. 3 Global Kaposi Sarcoma Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Chemotherapy Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Alkaloids Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Liposomal Anthracyclines Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Immunotherapy Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global HAART Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Radiation Therapy Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Surgical Procedures Market, 2015 – 2025 (US$ Mn)
FIG. 13 U.S. Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 14 Canada Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 15 U.K. Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 16 Germany Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 17 France Kaposi Sarcoma Market, 2015-2025 (US$ Mn)
FIG. 18 Rest of Europe Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 19 Japan Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 20 China Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 21 India Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Asia Pacific Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 23 Brazil Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 24 Mexico Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 25 Rest of Latin America Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 26 GCC Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Middle East and Africa Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 2 Global Kaposi Sarcoma Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 4 North America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 6 Mn)
TABLE 7 Europe Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Kaposi Sarcoma Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 Aphios Corp.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Bristol Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Cytori Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 CytRx Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Eli Lilly and Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 F.Hoffman La-Roche, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)